Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized peptide vaccination with GM-CSF in children with relapsed acute lymphoblastic leukemia
2015-005281-29Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in acute lymphoblastic leukemia (ALL), sponsored by University Hospital Tübingen. Primary endpoints: Success of treatment, Safety and clinical toxicity and 1 more. Started Jan 2016; status: completed.
02
Drugs
sargramostim
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2015-005281-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005281-29.